Seneca Therapeutics
Developing advanced oncolytic immunotherapeutics for targeted solid cancer treatments.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| N/A | €0.0 | round | |
* | $190k Valuation: $35.0m | Seed | |
| Total Funding | 000k | ||
Related Content
Seneca Therapeutics is a biotechnology company specializing in the development of oncolytic viruses for the treatment of solid tumors. The company's lead asset, SVV-001, is an oncolytic virus that selectively replicates in certain human tumor cells, specifically those expressing the TEM 8 receptor. This virus is non-pathogenic in humans and animals, making it a promising candidate for cancer therapy. The company operates in the oncology market, targeting patients with solid tumors who may benefit from advanced immunotherapeutic treatments.
Seneca Therapeutics primarily serves the healthcare sector, including hospitals, cancer treatment centers, and research institutions. The business model revolves around the development and clinical trials of its proprietary oncolytic virus, SVV-001, with the aim of achieving regulatory approval and commercialization. Revenue generation is expected to come from partnerships, licensing agreements, and eventual sales of the therapeutic once it reaches the market.
The company's leadership team includes experienced professionals from the pharmaceutical and biotech industries, such as CEO Jim Hussey and Chief Medical Officer Dr. Sankar. They are focused on advancing SVV-001 through clinical trials and exploring strategic business development opportunities to secure funding and partnerships.
Keywords: oncolytic virus, solid tumors, cancer therapy, TEM 8 receptor, SVV-001, biotechnology, immunotherapy, clinical trials, oncology market, targeted treatment.